Sorafenib (Doxorubicin) is an oral multi-target, multi-kinase inhibitor that blocks tumor angiogenesis by inhibiting both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), and inhibits tumor cell proliferation by blocking the Raf/MEK/ERK signaling pathway, thereby exerting a dual-inhibitory, multi-target blocking effect against HCC. It can also inhibit tumor cell proliferation by blocking the Raf/MEK/ERK signaling pathway, thus exerting a dual inhibitory and multi-targeted anti-HCC effect. A number of international multicenter phase III clinical studies have demonstrated that sorafenib can delay the progression of hepatocellular carcinoma and renal carcinoma and significantly prolong the survival of patients with advanced disease, and has a good safety profile. The routine use of sorafenib is 400 mg, po. Bid; the effect on liver function should be taken into account when applying the drug, which requires patients with Child-Pugh A or relatively good B grade liver function. The combination of sorafenib with hepatic artery intervention or systemic chemotherapy may provide more benefit to patients, as has been confirmed by several clinical observations and studies. Indications for Doxorubicin】 1.Treatment of inoperable advanced renal cell carcinoma. 2.Treatment of inoperable or distant metastatic primary hepatocellular carcinoma.